Clinical Trial Update: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for tegavivint in relapsed or refractory diffuse large B-cell lymphoma, with ongoing recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma Activated B-cell Type
• Diffuse Large B-cell Lymphoma Germinal Center B-cell Type
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Transformed Indolent B-cell Non-hodgkin Lymphoma to Diffuse Large B-cell Lymphoma

Drugs mentioned

• Tegavivint

Snippet

Sponsor: Lapo Alinari | Conditions: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Status: RECRUITING